Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma

Huang,Lihua; Wang,Xuming; Huang,Xuan; Gui,Huawei; Li,Yan; Chen,Qiongxia; Liu,Dongling; Liu,Lijiang

doi:10.3892/ol.2018.7873

Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma

Authors:
- Lihua Huang
- Xuming Wang
- Xuan Huang
- Huawei Gui
- Yan Li
- Qiongxia Chen
- Dongling Liu
- Lijiang Liu
View Affiliations

Affiliations: Department of Pathology, Wuhan Puai Hospital, Wuhan, Hubei 430030, P.R. China, Department of Histopathology, Jiangda Pathology Institute, Jianghan University, Wuhan, Hubei 430056, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/ol.2018.7873
Pages: 4269-4277
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the rate of BRAF mutation and the expression profiles of CK19, galectin‑3, CD56, thyroid peroxidase (TPO) and Ki67 in papillary thyroid carcinoma (PTC) and papillary thyroid micro‑carcinoma (PTMC). A total of 246 cases of thyroid disease were collected, including PTC, PTMC, nodular goiter (NG) and Hashimoto thyroiditis (HT). The results revealed that CK19 expression was 116/120 in PTC, 61/64 in PTMC, 2/34 in NG and 1/28 in HT. Galectin‑3 positive expression was 115/120 in PTC, 60/64 in PTMC, 6/34 in NG and 4/28 in HT. TPO positive expression was 8/120 in PTC, 1/64 in PTMC, 30/34 in NG and 25/28 in HT. CD56-positive expression was 12/120 in PTC, 3/64 in PTMC, 33/34 in NG and 26/28 in HT. Ki67 labeling index was 2.52±0.46% in PTC (120 cases), 2.62±0.52% in PTMC (64 cases), 2.55±0.44% in NG (34 cases) and 2.58±0.48% in HT (28 cases). BRAF mutation rate was 93/120 in PTC, 47/64 in PTMC, 3/34 in NG and 2/28 in HT. These results suggested that expression patterns of CK19, galectin‑3, CD56 and TPO and BRAF mutation exhibit diagnosis value in thyroid disease. However, Ki67-positive rate exhibits no notable diagnosis value in thyroid disease.

View Figures

View References

1	Ito Y, Nikiforov YE, Schlumberger M and Vigneri R: Increasing incidence of thyroid cancer: Controversies explored. Nat Rev Endocrinol. 9:178–184. 2013. View Article : Google Scholar : PubMed/NCBI
2	Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG and Lee JS: Cancer statistics in Korea: Incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 45:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ito Y, Fukushima M, Higashiyama T, Kihara M, Takamura Y, Kobayashi K, Miya A and Miyauchi A: Incidence and predictors of right paraesophageal lymph node metastasis of N0 papillary thyroid carcinoma located in the right lobe. Endocr J. 60:389–392. 2013. View Article : Google Scholar : PubMed/NCBI
4	Joshi P, Nair S, Nair D and Chaturvedi P: Incidence of occult papillary carcinoma of thyroid in Indian population: Case series and review of literature. J Cancer Res Ther. 10:693–695. 2014.PubMed/NCBI
5	Wang J, Gao L, Song C and Xie L: Incidence of metastases from 524 patients with papillary thyroid carcinoma in cervical lymph nodes posterior to the sternoclavicular joint (level VIa): Relevance for endoscopic thyroidectomy. Surgery. 159:1557–1564. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhu J, Wang X, Zhang X, Li P and Hou H: Clinicopathological features of recurrent papillary thyroid cancer. Diagn Pathol. 10:962015. View Article : Google Scholar : PubMed/NCBI
7	Liu X, Ouyang D, Li H, Zhang R, Lv Y, Yang A and Xie C: Papillary thyroid cancer: Dual-energy spectral CT quantitative parameters for preoperative diagnosis of metastasis to the cervical lymph nodes. Radiology. 275:167–176. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zhang YZ, Qin F, Han ZG, Liu Q, Zhou L and Wang YW: Prognostic significance of DLL4 expression in papillary thyroid cancer. Eur Rev Med Pharmacol Sci. 19:2901–2905. 2015.PubMed/NCBI
9	Zhou SF, Hu SY, Ma L, Miao L and Mao WZ: Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2. Chin Med J (Engl). 126:1925–1929. 2013.PubMed/NCBI
10	Zhu Y, Wang C, Zhang GN, Shi Y, Xu SQ, Jia SJ and He R: Papillary thyroid cancer located in malignant struma ovarii with omentum metastasis: A case report and review of the literature. World J Surg Oncol. 14:172016. View Article : Google Scholar : PubMed/NCBI
11	Shi RL, Qu N, Liao T, Wang YL, Wang Y, Sun GH and Ji QH: Expression, clinical significance and mechanism of Slit2 in papillary thyroid cancer. Int J Oncol. 48:2055–2062. 2016. View Article : Google Scholar : PubMed/NCBI
12	Shi RL, Qu N, Liao T, Wei WJ, Lu ZW, Ma B, Wang YL and Ji QH: Relationship of body mass index with BRAF (V600E) mutation in papillary thyroid cancer. Tumour Biol. 37:8383–8390. 2016. View Article : Google Scholar : PubMed/NCBI
13	Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, et al: Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab. 101:264–274. 2016. View Article : Google Scholar : PubMed/NCBI
14	Su X, Li Z, He C, Chen W, Fu X and Yang A: Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: A meta-analysis. Oncotarget. 7:16716–16730. 2016.PubMed/NCBI
15	Gao B, Tian W, Jiang Y, Zhang X, Zhao J, Zhang S, Chen J and Luo D: Peri-operative treatment of giant nodular goiter. Int J Med Sci. 9:778–785. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tan Z, Ge MH, Zheng CM, Wang QL, Nie XL and Jiang LH: The significance of Delphian lymph node in papillary thyroid cancer. Asia Pac J Clin Oncol. 13:e389–e393. 2017. View Article : Google Scholar : PubMed/NCBI
17	Ma YJ, Deng XL and Li HQ: BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 35:591–599. 2015. View Article : Google Scholar : PubMed/NCBI
18	Lu ZZ, Zhang Y, Wei SF, Li DS, Zhu QH, Sun SJ, Li M and Li LI: Outcome of papillary thyroid microcarcinoma: Study of 1,990 cases. Mol Clin Oncol. 3:672–676. 2015. View Article : Google Scholar : PubMed/NCBI
19	Qu N, Zhang L, Ji QH, Chen JY, Zhu YX, Cao YM and Shen Q: Risk factors for central compartment lymph node metastasis in papillary thyroid microcarcinoma: A meta-analysis. World J Surg. 39:2459–2470. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang LY, Liu ZW, Liu YW, Gao WS and Zheng CJ: Risk factors for nodal metastasis in cN0 papillary thyroid microcarcinoma. Asian Pac J Cancer Prev. 16:3361–3363. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhang L, Liu Z, Liu Y, Gao W and Zheng C: The clinical prognosis of patients with cN0 papillary thyroid microcarcinoma by central neck dissection. World J Surg Oncol. 13:1382015. View Article : Google Scholar : PubMed/NCBI
22	Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, Chung JK, Youn YK, Kim KH, Park DJ and Cho BY: Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck. 32:38–45. 2010.PubMed/NCBI
23	Arora N, Turbendian HK, Kato MA, Moo TA, Zarnegar R and Fahey TJ III: Papillary thyroid carcinoma and microcarcinoma: Is there a need to distinguish the two? Thyroid. 19:473–477. 2009. View Article : Google Scholar : PubMed/NCBI
24	Batistatou A, Charalabopoulos K, Nakanishi Y, Vagianos C, Hirohashi S, Agnantis NJ and Scopa CD: Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: Correlation with E-cadherin. Endocr Pathol. 19:197–202. 2008. View Article : Google Scholar : PubMed/NCBI
25	Antonaci A, Consorti F, Mardente S, Natalizi S, Giovannone G and Della Rocca C: Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol Rep. 20:63–67. 2008.PubMed/NCBI
26	Kandogan T, Erkan N and Vardar E: Papillary carcinoma arising in a thyroglossal duct cyst with associated microcarcinoma of the thyroid and without cervical lymph node metastasis: A case report. J Med Case Rep. 2:422008. View Article : Google Scholar : PubMed/NCBI
27	Barbaro D, Simi U, Meucci G, Lapi P, Orsini P and Pasquini C: Thyroid papillary cancers: Microcarcinoma and carcinoma, incidental cancers and non-incidental cancers-are they different diseases? Clin Endocrinol (Oxf). 63:577–581. 2005. View Article : Google Scholar : PubMed/NCBI
28	Schneider DF and Chen H: New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin. 63:374–394. 2013. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Romero-Rojas A, Cuervo-Martínez J, Osorio-Arango K and Olaya N: Histological variants and prognostic factors of papillary thyroid carcinoma at the Colombian Instituto Nacional de Cancerologia, 2006–2012. Biomedica. 35:429–436. 2015. View Article : Google Scholar : PubMed/NCBI
31	Sak SD: Variants of papillary thyroid carcinoma: Multiple faces of a familiar tumor. Turk Patoloji Derg. 31 Suppl 1:S34–S47. 2015.
32	Lee JH, Shin JH, Lee HW, Oh YL, Hahn SY and Ko EY: Sonographic and cytopathologic correlation of papillary thyroid carcinoma variants. J Ultrasound Med. 34:1–15. 2015. View Article : Google Scholar : PubMed/NCBI
33	Song Q, Wang D, Lou Y, Li C, Fang C, He X and Li J: Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 6:1262011. View Article : Google Scholar : PubMed/NCBI
34	Gong L, Chen P, Liu X, Han Y, Zhou Y, Zhang W, Li H, Li C and Xie J: Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma. Gland Surg. 1:25–32. 2012.PubMed/NCBI
35	Liu Z, Yu P, Xiong Y, Zeng W, Li X, Maiaiti Y, Wang S, Song H, Shi L, Liu C, et al: Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma. Int J Clin Exp Med. 8:4369–4374. 2015.PubMed/NCBI
36	Laco J, Ryska A, Cap J and Celakovský P: Expression of galectin-3, cytokeratin 19, neural cell adhesion molecule and E-cadhedrin in certain variants of papillary thyroid carcinoma. Cesk Patol. 44:103–107. 2008.PubMed/NCBI
37	Nasr MR, Mukhopadhyay S, Zhang S and Katzenstein AL: Absence of the BRAF mutation in HBME1⁺ and CK19⁺ atypical cell clusters in Hashimoto thyroiditis: Supportive evidence against preneoplastic change. Am J Clin Pathol. 132:906–912. 2009. View Article : Google Scholar : PubMed/NCBI
38	Lamba Saini M, Weynand B, Rahier J, Mourad M, Hamoir M and Marbaix E: Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential. Diagn Pathol. 10:322015. View Article : Google Scholar : PubMed/NCBI
39	de Oliveira JT, Ribeiro C, Barros R, Gomes C, de Matos AJ, Reis CA, Rutteman GR and Gärtner F: Hypoxia up-regulates galectin-3 in mammary tumor progression and metastasis. PloS One. 10:e01344582015. View Article : Google Scholar : PubMed/NCBI
40	Ma H, Yan J, Zhang C, Qin S, Qin L, Liu L, Wang X and Li N: Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis. Int J Clin Exp Pathol. 7:7999–8007. 2014.PubMed/NCBI
41	Tang W, Huang C, Tang C, Xu J and Wang H: Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: A meta-analysis. OncoTargets Ther. 9:455–460. 2016. View Article : Google Scholar
42	Gweon HM, Kim JA, Youk JH, Hong SW, Lim BJ, Yoon SO, Park YM and Son EJ: Can galectin-3 be a useful marker for conventional papillary thyroid microcarcinoma? Diagn Cytopathol. 44:103–107. 2016. View Article : Google Scholar : PubMed/NCBI
43	Londero SC, Godballe C, Krogdahl A, Bastholt L, Specht L, Sørensen CH, Pedersen HB, Pedersen U and Christiansen P: Papillary microcarcinoma of the thyroid gland: Is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol. 47:451–457. 2008. View Article : Google Scholar : PubMed/NCBI
44	Dunđerović D, Lipkovski JM, Boričic I, Soldatović I, Božic V, Cvejić D and Tatić S: Defining the value of CD56, CK19, galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Diagn Pathol. 10:1962015. View Article : Google Scholar : PubMed/NCBI
45	Tong J, Wang Y and Da JP: Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions. Zhonghua Zhong Liu Za Zhi. 33:599–604. 2011.(In Chinese). PubMed/NCBI
46	Caballero Y, López-Tomassetti EM, Favre J, Santana JR, Cabrera JJ and Hernández JR: The value of thyroperoxidase as a prognostic factor for differentiated thyroid cancer-a long-term follow-up study. Thyroid Res. 8:122015. View Article : Google Scholar : PubMed/NCBI
47	Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, et al: Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med. 7:2304–2308. 2014.PubMed/NCBI
48	Yang QX, Shao CK, Feng ZY, Huang BQ, Han AJ, Xiong M, Zhao WL and Wu TT: Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases. Di Yi Jun Yi Da Xue Xue Bao. 25:678–681. 2005.(In Chinese). PubMed/NCBI
49	Bizzarro T, Martini M, Marrocco C, D'Amato D, Traini E, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM and Rossi ED: The role of CD56 in thyroid fine needle aspiration cytology: A pilot study performed on liquid based cytology. PloS One. 10:e01329392015. View Article : Google Scholar : PubMed/NCBI
50	Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A and Ruco L: Papillary carcinoma of the thyroid: Low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol. 212:411–419. 2007. View Article : Google Scholar : PubMed/NCBI
51	Zhou Y, Jiang HG, Lu N, Lu BH and Chen ZH: Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. Asian Pac J Cancer Prev. 16:1605–1608. 2015. View Article : Google Scholar : PubMed/NCBI
52	Lubitz CC, Economopoulos KP, Pawlak AC, Lynch K, Dias-Santagata D, Faquin WC and Sadow PM: Hobnail variant of papillary thyroid carcinoma: An institutional case series and molecular profile. Thyroid. 24:958–965. 2014. View Article : Google Scholar : PubMed/NCBI
53	Clinckspoor I, Hauben E, Verlinden L, Van den Bruel A, Vanwalleghem L, Vander Poorten V, Delaere P, Mathieu C, Verstuyf A and Decallonne B: Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem. 60:502–511. 2012. View Article : Google Scholar : PubMed/NCBI
54	Huang Y, Dong W, Li J, Zhang H, Shan Z and Teng W: Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma. BMC Cancer. 14:3832014. View Article : Google Scholar : PubMed/NCBI
55	Rossi M, Buratto M, Tagliati F, Rossi R, Lupo S, Trasforini G, Lanza G, Franceschetti P, Bruni S, Degli Uberti E and Zatelli MC: Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Thyroid. 25:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
56	Koochak A, Rakhshani N, Karbalaie Niya MH, Tameshkel FS, Sohrabi MR, Babaee MR, Rezvani H, Bahar B, Imanzade F, Zamani F, et al: Mutation analysis of KRAS and BRAF genes in metastatic colorectal cancer: A first large scale study from Iran. Asian Pac J Cancer Prev. 17:603–608. 2016. View Article : Google Scholar : PubMed/NCBI
57	Gertz RJ, Nikiforov Y, Rehrauer W, McDaniel L and Lloyd RV: Mutation in BRAF and other members of the MAPK pathway in papillary thyroid carcinoma in the pediatric population. Arch Pathol Lab Med. 140:134–139. 2016. View Article : Google Scholar : PubMed/NCBI
58	Kowalska A, Walczyk A, Kowalik A, Pałyga I, Trybek T, Kopczyński J, Kajor M, Chrapek M, Pięciak L, Chłopek M, et al: Increase in papillary thyroid cancer incidence is accompanied by changes in the frequency of the BRAF V600E mutation: A single-institution study. Thyroid. 26:543–551. 2016. View Article : Google Scholar : PubMed/NCBI
59	Sun Y, Shi C, Shi T, Yu J and Li Z: Correlation between the BRAF(v600E) gene mutation and factors influencing the prognosis of papillary thyroid microcarcinoma. Int J Clin Exp Med. 8:22525–22528. 2015.PubMed/NCBI
60	Li J, Zhang S, Zheng S, Zhang D and Qiu X: The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: A meta analysis. Int J Clin Exp Med. 8:22246–22253. 2015.PubMed/NCBI
61	Fu QF, Pan PT, Zhou L, Liu XL, Guo F, Wang L and Sun H: Clinical significance of preoperative detection of serum p53 antibodies and BRAF(V600E) mutation in patients with papillary thyroid carcinoma. Int J Clin Exp Med. 8:21327–21334. 2015.PubMed/NCBI
62	Kowalska A, Kowalik A, Pałyga I, Walczyk A, Gąsior-Perczak D, Kopczyński J, Lizis-Kolus K, Szyska-Skrobot D, Hurej S, Radowicz-Chil A, et al: The usefulness of determining the presence of BRAF V600E mutation in fine-needle aspiration cytology in indeterminate cytological results. Endokrynol Pol. 67:41–47. 2016. View Article : Google Scholar : PubMed/NCBI
63	Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L and Strupas K: The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer. Endokrynol Pol. 67:35–40. 2016. View Article : Google Scholar : PubMed/NCBI
64	Tan J: Perianal melanoma with a BRAF gene mutation in a young Portuguese Roma native. BMJ Case Rep. 2016:bcr20152127722016. View Article : Google Scholar : PubMed/NCBI
65	Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF and Shi Y: Concomitant RAS RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 24:1256–1266. 2014. View Article : Google Scholar : PubMed/NCBI
66	Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM and Clayman GL: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 15:485–491. 2009. View Article : Google Scholar : PubMed/NCBI
67	Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, Xu H, Xing M and Qu S: BRAFV600E mutation in papillary thyroid microcarcinoma: A meta-analysis. Endocr Relat Cancer. 22:159–168. 2015. View Article : Google Scholar : PubMed/NCBI
68	Syrenicz A, Koziołek M, Ciechanowicz A, Sieradzka A, Bińczak-Kuleta A and Parczewski M: New insights into the diagnosis of nodular goiter. Thyroid Res. 7:62014. View Article : Google Scholar : PubMed/NCBI